Revolution Medicines
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 378
- Market Cap
- $7.2B
- Website
- http://www.revmed.com
- Introduction
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanis...
Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- First Posted Date
- 2024-10-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 460
- Registration Number
- NCT06625320
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid Tumors
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 406
- Registration Number
- NCT06445062
- Locations
- 🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States
🇺🇸University of Colorado Hospital-Anschutz Cancer Pavilion, Aurora, Colorado, United States
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT06162221
- Locations
- 🇺🇸
Cancer Specialists of North Florida, St Augustine, Florida, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇩🇪Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, Germany
Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 210
- Registration Number
- NCT06128551
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC IRVINE Health, Orange, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 444
- Registration Number
- NCT06040541
- Locations
- 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Smilow Cancer Hospital (Yale University), New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 222
- Registration Number
- NCT05462717
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
🇺🇸University of Miami School of Medicine Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Conditions
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 614
- Registration Number
- NCT05379985
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UCLA, Santa Monica, California, United States
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05054725
- Locations
- 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸Hematology Oncology Clinic, Baton Rouge, Louisiana, United States
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT04774952
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸UC Irvine - Chao Family Comprehensive Cancer Center, Irvine, California, United States
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
- First Posted Date
- 2019-06-18
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT03989115
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States